Enliven Therapeutics, Inc. Common Stock
$49.45
-$0.79 (-1.57%)
$49.19Day Range$51.20
Key Statistics
Market Cap
$3.68B
Shares Outstanding
73.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 24, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$50.15
Day High
$51.20
Day Low
$49.19
Volume
6.01M
VWAP
$49.55
Prev Close
$50.24
Transactions
--
Acc. Volume
--
About Enliven Therapeutics, Inc. Common Stock
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
PHARMACEUTICAL PREPARATIONSSIC 283467 employees205 PARK ROAD, BURLINGAME, CA, 94010650-547-5814IPO Feb 24, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001672619
- Composite FIGI
- BBG00CP3BDD4
- Share Class FIGI
- BBG00CP3BDF2
- Ticker Root
- ELVN
- SIC Code
- 2834
About Enliven Therapeutics, Inc. Common Stock (ELVN) Stock
Enliven Therapeutics, Inc. Common Stock (ELVN) closed the 2026-09-18 session at $49.45, down 1.57% versus the previous close (-0.79). The stock opened at $50.15 and traded between $49.19 and $51.20 during that session. Session trading volume was 6.0M shares. The volume-weighted average price (VWAP) is $49.55.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics, Inc. Common Stock has a market capitalization of $3.68 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ELVN is listed on the XNAS exchange. The company employs approximately 67 people. Enliven Therapeutics, Inc. Common Stock is headquartered in BURLINGAME, CA. The recorded listing date is 2023-02-24.
On this page you can find market ELVN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.